Clinical Trials
Triumvira Immunologics Announces Publication Demonstrating the Safety and Efficacy of TAC T Cells Targeting Claudin 18.2
Triumvira Immunologics Inc.
PR-10-24-NI-47Oct 16, 2024
Roundtable
What do you see as the most significant regulatory decision or guidance on the horizon for 2024 (or beyond)?
Pharma's Almanac
PAO-12-23-RT-02Dec 15, 2023
Real-World Data
How Is Your Organization Currently Leveraging Real-World Data/Evidence and What Uses Do You Anticipate in the Future?
Pharma's Almanac
PAO-09-23-RT-01Sep 15, 2023
Financing
Bayer and Northpond Ventures Lead USD $55 Million Series A Financing Round for Triumvira Immunologics
Triumvira Immunologics Inc.
PR-M08-20-NI-45Aug 28, 2020